AstraZeneca stock tracks a USD 2.0 billion cancer deal
Published on 09/30/2026 at 12:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca (ISIN GB0009895292) was trading at EUR 144.53 at Lang & Schwarz on September 30, 2026 at 12:48 p.m. CEST, down 0.39 percent versus the prior close of EUR 145.10. The immediate company story is a USD 2.0 billion oncology investment in Summit Therapeutics announced on September 28, 2026. Reuters reported that the partnership will test combinations of Summit's ivonescimab with AstraZeneca cancer medicines.
USD 2.0 billion expands oncology reach
The transaction gives AstraZeneca rights equivalent to 12.0 percent of Summit's outstanding common stock, or 10.6 percent on a fully diluted basis, according to Halifax on September 29, 2026. The two companies plan clinical trials combining ivonescimab with sonesitatug vedotin, AstraZeneca's investigational antibody drug conjugate for gastrointestinal cancers.
The structure links a direct equity investment with shared development work. Each company retains development and commercial rights to its own medicine, while the proposed combinations could broaden AstraZeneca's use of antibody drug conjugates across tumor types, Reuters reported on September 28, 2026.
Analysts split on the deal
finanzen.ch reported on September 30, 2026, that Deutsche Bank Research kept AstraZeneca at Hold with a GBp 11,700.00 price target. Analyst Emmanuel Papadakis viewed the Summit transaction negatively, describing it as evidence that AstraZeneca may have been late to the bispecific cancer-antibody field.
The counterpoint came from Jefferies on September 29, 2026. According to finanzen.ch, the firm retained a Buy rating and a GBp 17,500.00 target, calling the deal strategically smart because it provides access to ivonescimab for combination therapies.
October events set the next checkpoints
AstraZeneca's investor-relations calendar lists a Barclays Cardio Pipeline Investor Call for October 5, 2026, followed by a Meet the Management event at ASBMR on October 12, 2026. The company presents those dates on its AstraZeneca investor-relations page.
Stock trades at EUR 144.53
AstraZeneca stock was trading at EUR 144.53 at Lang & Schwarz on September 30, 2026 at 12:48 p.m. CEST. The price was down 0.39 percent against the Lang & Schwarz prior close of EUR 145.10 on September 29, 2026, keeping the market reaction measured while investors assess the Summit terms.
AstraZeneca stock facts
- Company: AstraZeneca PLC
- ISIN: GB0009895292
- Ticker: AZN.L
- Primary exchange: London Stock Exchange
- Price Lang & Schwarz (as of September 30, 2026, 12:48 p.m. CEST): EUR 144.53
- Change versus prior close: minus 0.39 percent
- Prior close Lang & Schwarz (September 29, 2026): EUR 145.10
- Market capitalization: USD 254.7 billion (as of September 29, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
